Conditions: Inflammation Barrett's Esophagus
Keywords: Barrett's Esophagus Radiofrequency ablation Patients post-radiofrequency ablation for Barrett's Esophagus.
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 30
Healthy volunteers: no

Brief summary:
The investigators hypothesize that intensive acid suppression with a long acting high potency proton pump inhibitor (PPI) drug dexlansoprazole will lead to a greater decrease in levels of inflammatory mediators (compared to conventional PPIs) in the esophagus, which could potentially lead to decreased recurrence of intestinal metaplasia following endoscopic ablation.

Detailed description:
Patients who achieve complete remission of intestinal metaplasia following ablation will be randomized (using concealed allocation, like the flip of a coin) to either intensive acid suppression with dexlansoprazole 60-90 mg/day or to symptom guided acid suppression with escalating doses of omeprazole (20-60 mg/day) for 6 months. Control of reflux will be assessed using 24 hour ambulatory pH monitoring. The need to escalate drug dosage at the 3 month visit will be determined by presence of excessive acid exposure on ambulatory pH monitoring. Biopsies of esophageal tissue will be obtained at baseline, then at 3 months and 6 months following randomization to measure changes in inflammatory biomarkers.

Arms:
arm 1: Participants will be treated with dexlansoprazole 60-90 mg/day for 6 months arm 2: Participants will be treated with omeprazole 20mg/day for a minimum of 6 weeks. If symptomatic can increase dose by 20mg twice.

Interventions: intervention 1: dexlansoprazole intervention 2: Omeprazole
Intervention descriptions: intervention 1: Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months intervention 2: Escalating doses of omeprazole (20-60 mg/day) for 6 months

Protocol document: